Avasarala, J. 2017. Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill. Drug Target Insights. 11, 1 (Nov. 2017). DOI:https://doi.org/10.33393/dti.2017.1367.